12:13 PM EDT, 07/31/2025 (MT Newswires) -- Myriad Genetics ( MYGN ) said Thursday it secured a new five-year, $200 million senior secured term loan credit facility from OrbiMed to support its growth strategy.

The agreement includes $125 million in initial funding, with the option to draw an additional $75 million through June 30, 2027.

The loan matures July 31, 2030, and carries an interest rate based on the one-month secured overnight financing rate plus 6.50%, with a secured overnight financing rate floor of 2.50%, the company said.

Shares of Myriad Genetics ( MYGN ) were down nearly 3% in recent trading.

Price: 3.94, Change: -0.12, Percent Change: -2.84